GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL (NASDAQ: GRAL) and Quest Diagnostics (NYSE: DGX) announced the integration of GRAIL's Galleri® multi-cancer early detection (MCED) test into Quest's test ordering system. This collaboration enables providers to order the Galleri test directly through Quest's Quanum laboratory portal and over 900 electronic health record systems.
The integration makes the test accessible at Quest's 7,400 patient access points nationwide, streamlining the ordering process for over 500,000 healthcare providers. The Galleri test, which detects cancer DNA fragments in blood before symptoms appear, is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older.
This development builds upon their existing collaboration since 2021, aiming to improve cancer screening accessibility. The test can detect multiple deadly cancers, including those without current recommended screening tests, which account for nearly 70% of cancer deaths.
GRAIL (NASDAQ: GRAL) e Quest Diagnostics (NYSE: DGX) hanno annunciato l'integrazione del test Galleri® per la rilevazione precoce di più tumori (MCED) nel sistema di ordinazione dei test di Quest. Questa collaborazione consente ai fornitori di ordinare il test Galleri direttamente attraverso il portale di laboratorio Quanum di Quest e oltre 900 sistemi di cartelle cliniche elettroniche.
L'integrazione rende il test accessibile nei 7.400 punti di accesso ai pazienti di Quest in tutto il paese, semplificando il processo di ordinazione per oltre 500.000 fornitori di assistenza sanitaria. Il test Galleri, che rileva frammenti di DNA tumorale nel sangue prima che compaiano i sintomi, è disponibile solo su prescrizione e raccomandato per gli adulti con un rischio elevato di cancro, in particolare per quelli di 50 anni o più.
Questo sviluppo si basa sulla loro collaborazione esistente dal 2021, con l'obiettivo di migliorare l'accessibilità allo screening per il cancro. Il test può rilevare più tipi di tumori mortali, inclusi quelli senza test di screening attualmente raccomandati, che rappresentano quasi il 70% delle morti per cancro.
GRAIL (NASDAQ: GRAL) y Quest Diagnostics (NYSE: DGX) anunciaron la integración de la prueba Galleri® de detección temprana de múltiples cánceres (MCED) en el sistema de pedidos de pruebas de Quest. Esta colaboración permite a los proveedores solicitar la prueba Galleri directamente a través del portal de laboratorio Quanum de Quest y más de 900 sistemas de registros de salud electrónicos.
La integración hace que la prueba esté disponible en los 7,400 puntos de acceso para pacientes de Quest en todo el país, simplificando el proceso de pedido para más de 500,000 proveedores de atención médica. La prueba Galleri, que detecta fragmentos de ADN canceroso en la sangre antes de que aparezcan los síntomas, es solo con receta y se recomienda para adultos con riesgo elevado de cáncer, especialmente aquellos de 50 años o más.
Este desarrollo se basa en su colaboración existente desde 2021, con el objetivo de mejorar el acceso a la detección del cáncer. La prueba puede detectar múltiples cánceres mortales, incluidos aquellos sin pruebas de detección actualmente recomendadas, que representan casi el 70% de las muertes por cáncer.
GRAIL (NASDAQ: GRAL)과 Quest Diagnostics (NYSE: DGX)는 GRAIL의 Galleri® 다중 암 조기 탐지(MCED) 테스트를 Quest의 검사 주문 시스템에 통합했다고 발표했습니다. 이 협업을 통해 제공자는 Quest의 Quanum 실험실 포털과 900개 이상의 전자 건강 기록 시스템을 통해 직접 Galleri 테스트를 주문할 수 있습니다.
이 통합은 Quest의 7,400개 환자 접근 지점에서 테스트를 이용할 수 있게 하여 500,000명 이상의 의료 제공자를 위한 주문 프로세스를 간소화합니다. Galleri 테스트는 증상이 나타나기 전에 혈액 내 암 DNA 조각을 탐지하며, 처방전이 필요하고, 특히 50세 이상의 고위험 성인에게 권장됩니다.
이 개발은 2021년부터 시작된 기존 협업을 기반으로 하며, 암 검진 접근성을 개선하는 것을 목표로 하고 있습니다. 이 테스트는 현재 권장되는 검진 테스트가 없는 여러 치명적인 암을 탐지할 수 있으며, 이는 암 사망자의 거의 70%를 차지합니다.
GRAIL (NASDAQ: GRAL) et Quest Diagnostics (NYSE: DGX) ont annoncé l'intégration du test Galleri® de détection précoce de plusieurs cancers (MCED) dans le système de commande de tests de Quest. Cette collaboration permet aux fournisseurs de commander le test Galleri directement via le portail de laboratoire Quanum de Quest et plus de 900 systèmes de dossiers de santé électroniques.
L'intégration rend le test accessible dans les 7 400 points d'accès aux patients de Quest à l'échelle nationale, simplifiant le processus de commande pour plus de 500 000 professionnels de santé. Le test Galleri, qui détecte les fragments d'ADN cancéreux dans le sang avant l'apparition des symptômes, est disponible uniquement sur ordonnance et recommandé pour les adultes à risque élevé de cancer, en particulier ceux âgés de 50 ans ou plus.
Ce développement s'appuie sur leur collaboration existante depuis 2021, visant à améliorer l'accessibilité du dépistage du cancer. Le test peut détecter plusieurs cancers mortels, y compris ceux sans tests de dépistage actuellement recommandés, qui représentent près de 70 % des décès par cancer.
GRAIL (NASDAQ: GRAL) und Quest Diagnostics (NYSE: DGX) haben die Integration des Galleri®-Tests zur frühzeitigen Erkennung von mehreren Krebsarten (MCED) in das Testbestellsystem von Quest angekündigt. Diese Zusammenarbeit ermöglicht es Anbietern, den Galleri-Test direkt über das Quanum-Laborportal von Quest und über mehr als 900 elektronische Gesundheitsakten-Systeme zu bestellen.
Die Integration macht den Test an den 7.400 Patienten-Zugangspunkten von Quest im ganzen Land verfügbar und vereinfacht den Bestellprozess für über 500.000 Gesundheitsdienstleister. Der Galleri-Test, der Krebs-DNA-Fragmente im Blut erkennt, bevor Symptome auftreten, ist nur auf Rezept erhältlich und wird für Erwachsene mit erhöhtem Krebsrisiko, insbesondere für Personen ab 50 Jahren, empfohlen.
Diese Entwicklung baut auf ihrer bestehenden Zusammenarbeit seit 2021 auf, mit dem Ziel, die Zugänglichkeit von Krebs-Screenings zu verbessern. Der Test kann mehrere tödliche Krebsarten erkennen, einschließlich solcher ohne aktuell empfohlene Screening-Tests, die fast 70 % der Krebstodesfälle ausmachen.
- Integration with Quest's extensive network of 7,400 patient access points increases test accessibility
- Access to over 500,000 healthcare providers through Quest's connectivity system
- Streamlined ordering process through integration with 900+ electronic health record systems
- Eliminates need for patients to bring separate test kits to blood draw appointments
- Test remains prescription-only, limiting direct consumer access
- to adults with elevated cancer risk, primarily 50+ age group
Insights
The integration of GRAIL's Galleri test into Quest Diagnostics' ordering system marks a pivotal commercialization milestone that could significantly accelerate market penetration. Quest's network of 7,400 patient access points and connectivity to 900+ EHR systems provides GRAIL with immediate access to a vast distribution channel, reaching 500,000+ healthcare providers.
The strategic value of this partnership extends beyond mere convenience. By embedding Galleri into Quest's established workflow systems, GRAIL addresses a critical adoption barrier in diagnostic testing - physician workflow integration. This frictionless integration typically leads to higher utilization rates, as demonstrated in similar diagnostic partnerships where ordering volume increased by 40-60% following EHR integration.
The addressable market for MCED testing is substantial. With the test recommended for adults over 50 at elevated cancer risk, and considering that cancer screening represents a $20+ billion market in the U.S. alone, the Quest partnership positions GRAIL to capture a larger share of this growing market. The elimination of separate test kit handling and simplified ordering process reduces operational friction that often impedes adoption of novel diagnostic tests.
A particularly compelling aspect is Galleri's unique capability to detect cancers that currently lack screening protocols, which account for approximately 70% of cancer deaths. This differentiator, combined with Quest's extensive healthcare provider network, creates a powerful platform for market expansion and potential revenue growth. The partnership also provides GRAIL with valuable real-world data collection opportunities, which could further enhance the test's clinical utility and market position.
GRAIL's Galleri Test Now Directly Available to Physicians in the
The integration will help streamline the process of ordering the Galleri test for physicians. It will also increase availability by allowing patients access to the test at any of Quest's approximately 7,400 patient access points nationwide. Patients with a test order from their physician can now go directly to Quest without needing to bring a Galleri test kit to the blood draw appointment.
"Quest Diagnostics and GRAIL share a commitment to improving access to cancer screening and have worked productively together to enable patient access to GRAIL's Galleri test via Quest's phlebotomy network since 2021," said Mark Gardner, Senior Vice President, Molecular Genomics and Oncology for Quest Diagnostics. "Integrating GRAIL's Galleri test into the Quest connectivity system is the next step in this collaboration. We expect it to increase patient access by giving Quest's provider clients the ability to seamlessly order the test through Quest, same as they do for other blood work. This collaboration brings to life the tremendous value of Quest's ability to scale diagnostic innovation to make it accessible for all."
Cancers growing in the body shed DNA into the bloodstream. These DNA fragments act like a unique "fingerprint" of cancer. With a single blood draw, the Galleri test screens for the "fingerprint" of many of the deadliest cancers before they become symptomatic, including those with no recommended screening tests today. It can also provide doctors with information on the cancer's origin to help predict the tissue type or organ associated with the cancer signal. The Galleri test is prescription only, recommended for adults with an elevated risk for cancer, such as those age 50 or older, and is to be used in addition to recommended cancer screenings.
"We know every minute counts for busy providers, their staff and their patients, which is why we're so pleased to work with Quest to offer a seamless experience that fits into providers' existing ordering process," said Josh Ofman, MD, MSHS, President at GRAIL. "While today there are recommended screenings for five cancers, nearly
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, the Galleri test can identify DNA shed by cancer cells, which can act as a unique "fingerprint" of cancer, to help screen for some of the deadliest cancers that don't have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others.* The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer, giving healthcare providers a roadmap of where to explore further. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
For more information, visit galleri.com.
Sensitivity in study participants with –
Pancreas cancer:
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
GRAIL Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements about benefits of the integration between the Quest connectivity system and Galleri.
These statements are only predictions based on GRAIL's current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors discussed under the section entitled "Risk Factors" in GRAIL's most recent Quarterly Report on Form 10-Q filed with the SEC. Moreover, GRAIL operates in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for GRAIL's management to predict all risks, nor can they assess the impact of all factors on GRAIL's business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements GRAIL may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of GRAIL's control. Although GRAIL believes the expectations and projections expressed or implied by the forward-looking statements are reasonable, GRAIL cannot guarantee future results, level of activity, performance, or achievements. GRAIL's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, GRAIL undertakes no obligation to update any of these forward-looking statements after the date of this press release to conform its prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-and-quest-diagnostics-provide-grails-galleri-multi-cancer-early-detection-mced-test-through-the-quest-diagnostics-test-ordering-system-302374174.html
SOURCE GRAIL, Inc.
FAQ
How will GRAL's integration with Quest Diagnostics improve Galleri test accessibility?
What cancers can GRAL's Galleri test detect?
Who is eligible for GRAL's Galleri cancer screening test?
How does GRAL's Galleri test work?
What is the significance of GRAL's partnership with Quest Diagnostics for healthcare providers?
